|
Nov 30, 2022
|
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
|
|
|
Nov 09, 2022
|
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
|
|
|
Sep 08, 2022
|
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
|
|
|
Aug 22, 2022
|
Innoviva Completes Acquisition of La Jolla Pharmaceutical
|
|
|
Jul 27, 2022
|
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
|
|
|
Jul 13, 2022
|
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
|
|
|
Jul 11, 2022
|
Innoviva Completes Acquisition of Entasis Therapeutics
|
|
|
Jul 11, 2022
|
Innoviva to Acquire La Jolla Pharmaceutical Company
|
|
|
Jul 08, 2022
|
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
|
|
|
May 23, 2022
|
Innoviva to Acquire Entasis Therapeutics
|
|